Cipla updates on Stempeutics Research, a JV with Cipla Group

Cipla announced that Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group has been granted a US process patent for its novel stem-cell based drug Stempeucel by the United States Patent and Trademarks Office (USPTO).

Stempeucel will initially be used for the treatment of Critical Limb Ischemia (CLI) and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Powered by Capital Market - Live News